Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Zodiac Bio-Tech Limited has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This workload is managed by 1 distinct examiner, which shows a concentrated prosecution effort for the company's current applications. The involvement of 1 distinct art unit further indicates that the company's legal challenges are focused within a specific technical division of the patent office.
The busiest examiner for the portfolio is ZHU, JIANJIAN, who handles 1 busiest examiner pending office action. Since there is only 1 pending office action in total, this individual is responsible for the entire active workload. This concentration means the company's immediate success in the Biotechnology & Pharmaceuticals sector depends on the outcome of this 1 pending office action. With 1 distinct examiner and 1 distinct art unit, the prosecution environment is highly focused, requiring a precise strategy to address the 1 busiest examiner pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZHU, JIANJIAN | 1 | 58.8% | +82.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18853270 | USE OF EXTRACT FROM RABBIT SKIN INFLAMED BY VACCINIA VIRUS IN TREATMENT OF ALZHEIMER'S DISEASE | ZHU, JIANJIAN | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18853270 | USE OF EXTRACT FROM RABBIT SKIN INFLAMED BY VACCINIA VIRUS IN TREATMENT OF ALZHEIMER'S DISEASE | ZHU, JIANJIAN | 1632 | §102§103§112DP | Non-Final OA | — | Pending | Oct 01, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial